Mgrm Medicare Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Mgrm Medicare Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $2.2M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Mgrm Medicare Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $2.2M Trade | TransData Nexus

Mgrm Medicare Private Limited

Indian Pharmaceutical Exporter · Respiratory Specialist · $2.2M Total Trade · DGFT Verified

Mgrm Medicare Private Limited is an Indian pharmaceutical exporter with a total trade value of $2.2M across 2 products in 1 therapeutic categories. Based on 64 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Salbutamol ($1.8M), Ipratropium ($328.7K), .

Mgrm Medicare Private Limited — Export Portfolio & Destination Treemap

Mgrm Medicare Private Limited pharmaceutical export portfolio — 2 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is Mgrm Medicare Private Limited? — Company Overview & Market Position

Mgrm Medicare Private Limited, established on December 15, 1994, is a private limited company headquartered in Gurgaon, Haryana, India. The company specializes in manufacturing and exporting finished pharmaceutical formulations, focusing primarily on respiratory products.

As of March 2026, Mgrm Medicare has an authorized capital of ₹20.5 million and a paid-up capital of ₹8.42 million. The company employs approximately 52 professionals, reflecting its commitment to quality and innovation in the healthcare sector.

What Does Mgrm Medicare Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Salbutamol$1.8M 2Ipratropium$328.7K

Mgrm Medicare Private Limited Therapeutic Categories — 1 Specializations

Mgrm Medicare Private Limited operates across 1 therapeutic categories, with representing the largest segments by export value. The portfolio is concentrated — the top 5 products account for 100% of total exports.

Product Portfolio — Top 2 by Export Value

Mgrm Medicare Private Limited exports 2 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Salbutamol	Respiratory	$1.8M	54	1.2%	8
2	Ipratropium	Respiratory	$328.7K	10	0.6%	6

Mgrm Medicare Private Limited exports 2 pharmaceutical products across 1 therapeutic categories with a total export value of $2.2M. The top category is Respiratory (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Mgrm Medicare Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Mgrm Medicare operates manufacturing facilities in Gurgaon, Haryana, India. These facilities are equipped with advanced machinery and adhere to stringent quality control measures, ensuring the production of high-quality pharmaceutical formulations. The company's manufacturing processes are evaluated and accredited by international quality organizations, underscoring its commitment to excellence.

3Key Leadership

The leadership team at Mgrm Medicare comprises seasoned professionals with extensive experience in the healthcare industry. The current directors include:

Arunachalam Vimaladithan: Director since December 8, 2003.
Muralidhar Komanduri: Director since July 17, 2018.
Surabhi Dassharma: Director since October 1, 2008.
Sushant Murthy Komanduri: Additional Director since July 1, 2025.
Shivaksh Ahluwalia: Additional Director since September 2, 2025.

These leaders are instrumental in steering the company's strategic direction and operational success.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Mgrm Medicare Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Mgrm Medicare has made significant strides in regulated markets, obtaining approvals from various international regulatory bodies. In the United States, the company's products are approved by the Food and Drug Administration (FDA). In Europe, the products hold CE certification, and in Russia, they have passed toxicological and clinical trials.

These approvals facilitate Mgrm Medicare's entry into these markets, allowing the company to expand its global footprint and cater to a broader customer base.

2Emerging Markets

Mgrm Medicare has also focused on emerging markets, particularly in Africa, Latin America, and Southeast Asia. The company's adherence to the World Health Organization's Good Manufacturing Practice (GMP) standards enhances its credibility and facilitates market access in these regions.

By meeting international quality standards, Mgrm Medicare is well-positioned to serve the growing demand for quality pharmaceutical products in these emerging markets.

3Geographic Strategy

Mgrm Medicare's export strategy is characterized by a concentrated focus on respiratory products, with a total export value of $2.2 million across 64 shipments. This concentration indicates a strategic emphasis on a specific therapeutic area, potentially reducing diversification risks. However, it also suggests a need for portfolio diversification to mitigate market fluctuations and expand the company's reach.

Mgrm Medicare Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Mgrm Medicare's products are approved by the U.S. Food and Drug Administration (FDA), indicating compliance with stringent U.S. regulatory standards. This approval is crucial for market access in the United States, a key market for pharmaceutical products.

The company's adherence to FDA regulations underscores its commitment to quality and safety, enhancing its reputation in the global pharmaceutical industry.

2WHO & EU GMP

Mgrm Medicare's manufacturing processes are evaluated and accredited by international quality organizations, including the World Health Organization's Good Manufacturing Practice (GMP) standards. This accreditation reflects the company's commitment to maintaining high-quality manufacturing standards.

Additionally, the company's products hold CE certification, facilitating market access in European Union member countries.

3CDSCO & Indian Regulatory

Mgrm Medicare holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. This license is essential for the legal manufacture and distribution of pharmaceutical products within India.

Mgrm Medicare Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Mgrm Medicare operates in a competitive landscape, focusing on the respiratory therapeutic category. While specific competitors are not identified in the available data, the company's adherence to international quality standards, such as WHO GMP and CE certification, positions it favorably in the market.

The company's strategic focus on a niche therapeutic area may provide a competitive edge, allowing for specialized expertise and product offerings.

2Key Differentiators

Mgrm Medicare's key differentiators include its specialized focus on respiratory products and its adherence to international quality standards. The company's manufacturing processes are evaluated and accredited by international quality organizations, including the World Health Organization's Good Manufacturing Practice (GMP) standards.

These differentiators enhance the company's reputation and appeal to customers seeking high-quality pharmaceutical formulations.

3Strategic Position

Mgrm Medicare's current strategic direction emphasizes the production and export of respiratory pharmaceutical formulations. The company's adherence to international quality standards, such as WHO GMP and CE certification, supports this focus.

Buyer Due Diligence Brief — Evaluating Mgrm Medicare Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Mgrm Medicare's track record in manufacturing and exporting pharmaceutical formulations is commendable, with a total export value of $2.2 million across 64 shipments. The company's adherence to international quality standards, including WHO GMP and CE certification, underscores its commitment to quality and reliability.

These factors indicate that Mgrm Medicare is a reliable supplier capable of meeting international standards and customer expectations.

2Certifications to Verify

Importers should verify the following certifications when considering Mgrm Medicare as a supplier:

FDA Approval: Confirms compliance with U.S. regulatory standards.
WHO GMP Certification: Ensures adherence to international manufacturing practices.
CE Certification: Indicates compliance with European Union standards.

Verification can be conducted through the respective regulatory bodies' official channels or by requesting copies of the certificates directly from Mgrm Medicare.

Frequently Asked Questions — Mgrm Medicare Private Limited

How many pharmaceutical products does Mgrm Medicare Private Limited export from India?

Mgrm Medicare Private Limited exports 2 pharmaceutical products across 1 therapeutic categories. The top exports are Salbutamol ($1.8M), Ipratropium ($328.7K). Total export value is $2.2M.

What is Mgrm Medicare Private Limited's total pharmaceutical export value?

Mgrm Medicare Private Limited's total pharmaceutical export value is $2.2M, based on 64 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Mgrm Medicare Private Limited cover?

Mgrm Medicare Private Limited exports across 1 therapeutic categories. The largest are Respiratory (100.0%, 2 products).

Get Full Mgrm Medicare Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.